Table 2 |
||||
|
Material sampling and organ involvements in patients with IgG4-RD |
||||
|
Case |
Material sampling |
Organ involvement |
||
|
|
||||
|
PBMC |
CD3/CD20 |
LSGa |
||
|
|
||||
|
1 |
○ |
○ |
MD, lymph node, lung |
|
|
2 |
○ |
○ |
MD, lymph node |
|
|
3 |
○ |
○ |
MD |
|
|
4 |
○ |
MD, lymph node |
||
|
5 |
○ |
MD, lung |
||
|
6 |
○ |
○ |
MD, lymph node, para-aorta swelling |
|
|
7 |
○ |
○ |
Intraorbital mass, retroperitoneal fibrosis |
|
|
8 |
○ |
MD |
||
|
9 |
○ |
MD |
||
|
10 |
○ |
MD |
||
|
11 |
○ |
MD |
||
|
12 |
○ |
MD |
||
|
13 |
○ |
MD |
||
|
14 |
○ |
MD, lung |
||
|
15 |
○ |
MD, liver |
||
|
|
||||
|
PBMCs, peripheral blood mononuclear cells; CD3/CD20, CD3-positive T cells and CD20-positive B cells sorted from PBMCs; LSG, labial salivary gland; MD, Mikulicz disease (salivary and lacrimal glands). aAll LSG samples satisfied histopathologic findings of the comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD) 2011. |
||||
|
Tsuboi et al. Arthritis Research & Therapy 2012 14:R171 doi:10.1186/ar3924 |
||||